Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in Russia
A subset of patients (15 to 20%) with myasthenia gravis (MG) remains refractory to standard types of treatment. Analysis of efficiency of rituximab, a chimeric monoclonal antibody to surface antigen of B lymphocytes (CD20), in 16 patients suffering from refractory MG was performed. In all cases, the...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-09-01
|
Series: | Nervno-Myšečnye Bolezni |
Subjects: | |
Online Access: | https://nmb.abvpress.ru/jour/article/view/124 |